Furthermore, I-BET762 showed additive cytostatic or cytotoxic efficacy in combination with PARP inhibitor Talazoparib in all of the tested SCLC cell lines with an intact MYC signaling pathway. Here, MYC is linked to small cell lung carcinoma.